Clinical Trials Logo

Hemodialysis Complication clinical trials

View clinical trials related to Hemodialysis Complication.

Filter by:

NCT ID: NCT04063423 Completed - Clinical trials for End Stage Renal Disease

Non- Clinical Coagulation Activation During Hemodialysis

NC-Coact
Start date: October 25, 2018
Phase:
Study type: Observational

Every patient included in the study will undergo 1 conventional hemodialysis treatment, ie 1 study visit. During the conventional hemodialysis treatment lasting 4 hours, 2 blood samples will be taken at different time points (5 minutes after dialysis start and 240 minutes after dialysis = at the end of the dialysis session) to evaluate coagulation activation (TAT, PF1+2). Hemodialysis session parameters (arterial and venous pressure, TMP, OCM, BVM and prefilter pressure) will be noted at different time points (T5, T30, T60, T120, T180, T240). After discontinuation of the dialysis session, total cell volume will be measured using the Renatron II system® and the number of open fibers will be determined using micro-CT scanning.

NCT ID: NCT04057313 Completed - Clinical trials for Hemodialysis Complication

Coffee in Hemodialysis and Headache

CoffeeHD
Start date: September 1, 2019
Phase: N/A
Study type: Interventional

Coffee is the most consumed drink worldwide, sometimes needed to boost energy and other times to entertain social connectivity. Caffeine is mostly present unbound in the plasma, only 10 to 30% of caffeine binds to plasma proteins. It is distributed freely into the intracellular space, and it has a small distribution volume. Therefore, caffeine can pass through the dialysis membrane during a standard hemodialysis session. In hemodialysis patients, headache occurs in 40 to 75% of patients. Some authors have suggested that one of the reasons of headache during hemodialysis is caffeine withdrawal. This trial aims to find whether coffee intake during hemodialysis reduces the headache episodes. It is a randomized double blind multicenter trial where 160 patients will be randomized to 2 groups: group 1 of 80 patients will be given a cup of coffee each dialysis session for 4 weeks and group 2 will receive decaffeinated coffee each dialysis session for 4 weeks.

NCT ID: NCT04046042 Recruiting - Clinical trials for Hemodialysis Complication

Virtual Reality Intradialysis: Last vs. First Part of the Session

VRI
Start date: September 2, 2019
Phase: N/A
Study type: Interventional

The main objective of this investigation is to assess if an intradialysis virtual reality exercise program during the last two hours of the hemodialysis session results in greater hemodynamic stability than exercise performed during the first two hours of the hemodialysis session. The secondary aims are to assess the impact of intradialysis virtual reality exercise during the last two hours of the hemodialysis session on dialysis efficacy, postdialysis molecules rebound, adherence to exercise, functional capacity, physical activity level, health-related quality of life, cognitive function, morbidity, frailty and dependency. We will also analyze the reliability of muscle strength assessment of lower limb muscles with a handheld dynamometer during hemodialysis.

NCT ID: NCT03990142 Completed - Clinical trials for Hemodialysis Complication

Study of Abnormalities of the Nervous System in the Occurrence of Intradialytic Arterial Hypotension

SUDHEMO
Start date: June 25, 2019
Phase: N/A
Study type: Interventional

Intradialytic hypotension is a common complication of hemodialysis sessions in patients with chronic renal failure, with an estimated prevalence of 10 to 30%. This hypotensopn is classically defined by a decrease in systolic blood pressure greater than 30 mmHg associated with clinical signs (cramps, abdominal pain, unconsciousness, convulsions). Its repetition is correlated with cardiovascular events, neurological events and excess mortality. Several clinical factors have been proposed to predict the risk of intradialytic hypotension such as age, certain comorbidities (diabetes, ischemic heart disease...), dialysis modalities (hemodialysis), ultrafiltration, conductivity but also alterations of the autonomic nervous system (especially the sympathetic system). In recent years, the study of vegetative functions has been facilitated by the use of SUDOSCAN® (Impeto, Paris, France) which is a simple, non-invasive tool that allows the study of Chlorine conductance directly reflecting the activity of small non-myelinated C fibers that innervate the sweat glands. SUDOSCAN® has shown good sensitivity and specificity in the diagnosis of vegetative damage in diabetic patients and also a good correlation with cardiac autonomic neuropathy. More recently, SUDOSCAN® has shown good sensitivity in the detection of neuropathies small fibers especially in diabetic patients. This sensitivity is comparable to QST-type quantitative tests and the correlation with cardiovascular dysautonomia tests is good. This test, simple and fast realization, does not require the active participation of the patient. There is a good correlation between the results of SUDOSCAN® and the reduction of intra-dermal fiber density at cutaneous biopsy. Hemodialysis patients are at risk of peripheral neurological involvement not only because of an increasing incidence of diabetes (30-40%) but also because of the abnormal production and elimination of certain uremic toxins. Few studies exist on the anomalies of the vegetative system in hemodialysis. A recent publication has suggested a difference in nerve excitability depending on the type of hemodialysis suggesting nerve changes secondary to ionic changes. The identification of patients at risk of intradialytic hypotension during dialysis sessions could be useful for adapting hemodialysis protocols. Patients will be classified into 2 groups according to the occurrence of intradialytic hypotension. Group 1 corresponds to patients with intradialytic hypotension and group 2 corresponds to patients without intradialytic hypotension.

NCT ID: NCT03912727 Completed - Clinical trials for Hemodialysis Complication

Alpha Lipoic Acid Against Cardiovascular Events in Patients With Haemodialysis

Start date: April 11, 2019
Phase: N/A
Study type: Interventional

Evaluate the association between possible benefit effects of oral administration of alpha lipoic acid by patients with hemodialysis and the possible reduction in cardiovascular events (CVEs); using Advanced glycation end products (AGEs) as a measure to assess endothelium function which correlate with CVEs.

NCT ID: NCT03901794 Completed - Clinical trials for Hemodialysis Complication

Relationship Between Hemodynamic Change and Fluid Removed During Hemodialysis

Start date: May 6, 2017
Phase:
Study type: Observational

Relationship between hemodynamic change and fluid removed during hemodialysis measured by non-invasive monitor

NCT ID: NCT03887468 Completed - Clinical trials for End Stage Renal Disease

Hemodialysis Adequacy Using a Heparin-grafted Dialyzer and a Citrate-enriched Dialysate

EvoCit-HD
Start date: May 15, 2018
Phase: N/A
Study type: Interventional

After providing informed consent, patients will be randomized to either the intervention treatment ("EvoCit procedure") or the control treatment ("EvoHep procedure"). After randomization, each study arm consists of four weeks of 3x4 hours hemodialysis treatments according to the allocated protocol. After the last dialysis treatment of the fourth treatment week and after a long interdialytic interval, patients will crossover to the alternative hemodialysis procedure. After crossover, the study will be completed with, again, four weeks of 3x4 hours hemodialysis treatments according to the allocated protocol.

NCT ID: NCT03874819 Not yet recruiting - Clinical trials for Hemodialysis Complication

Effect of a Medium Cut-Off Dialyzer - Medical Device on ESA Resistance in 110 Hemodialysis Patients (EXPAND)

EXPAND
Start date: July 15, 2019
Phase: N/A
Study type: Interventional

It is hypothesized that a consistent use of Medium cut-off membrane (Theranova) increased clearance of pro-inflammatory molecules in a broad molecular weight range attenuates the chronic inflammatory state in patients with poor response to ESA therapy and absence of absolute iron deficiency and that this leads to an improvement in ESA responsiveness (EPO resistance index).

NCT ID: NCT03854513 Not yet recruiting - Clinical trials for Hemodialysis Complication

Impact of Residual Renal Function on Complications in Chronic Hemodialysis Patients

Start date: February 26, 2019
Phase:
Study type: Observational

Our aim is to study the impact of residual renal function on hemodialysis patients mortality and morbidity .

NCT ID: NCT03842657 Completed - Bleeding Clinical Trials

Regional Anticoagulation of Dialysis Circuits With a Calcium-free Citrate-containing Dialysate

C2D
Start date: July 5, 2019
Phase: Phase 2
Study type: Interventional

Critically ill patients have a high risk of bleeding but also require prolonged intermittent dialysis. Thus, a heparin-free easy-to-use alternative type of anticoagulation within the dialysis circuit is required. In a non-comparative study, heparin-free regional citrate anticoagulation of the dialysis circuit using a calcium-free citrate-containing dialysate, with calcium reinjected according to ionic dialysance, was considered as safe and efficient. The aim of this study is to confirm the superiority of this approach compared to a anticoagulation based on heparin-grafted membrane.